NCT06378346View on ClinicalTrials.gov

GU-01: Glycyrrhizin in Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Prostate Cancer
Interventions
OTHER

Observation

Participants will not receive glycyrrhizin

DRUG

Glycyrrhizin - 75 mg

Participants will either receive 75 mg orally daily

DRUG

Glycyrrhizin - 150 mg

Participants will receive 150 mg orally daily

Trial Locations (1)

60612

RECRUITING

University of Illinois, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER